Novo Nordisk's stock fell about 75% from its June 2024 peak of $148.15 to $37.98 by April 2026, driven by lowered market expectations for its weight management drug Wegovy. Despite this sharp decline, the company continues to generate strong free cash flow and maintains a solid 'AA' credit rating. The obesity care market, especially GLP-1 drug applications, remains a significant growth opportunity, supporting a positive outlook for Novo Nordisk alongside competitors like Eli Lilly. The analyst rates Novo Nordisk as a 'Buy' due to its favorable risk-reward profile at current prices.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
